ZyVersa Therapeutics, Inc.

ZVSA · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$9,413-$98,298-$14,048-$8,084
Dep. & Amort.$7$10$10$10
Deferred Tax$7-$9,479-$745-$442
Stock-Based Comp.$706$1,193$3,525$4,142
Change in WC$930$2,600$8,292-$1,020
Other Non-Cash$205$95,252-$1,922$318
Operating Cash Flow-$7,560-$8,721-$4,889-$5,076
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow$0$0$0$0
Financing Activities
Debt Repay.$0$0$0$5,230
Stock Issued$5,953$16,659$1,865$0
Stock Repurch.$0-$10,703$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$0-$12,151$1,965$0
Financing Cash Flow$5,953$5,956$1,865$5,230
Forex Effect$0$0$8,597$0
Net Chg. in Cash-$1,607-$2,765$5,574$154
Supplemental Information
Beg. Cash$3,138$5,902$329$175
End Cash$1,531$3,138$699$329
Free Cash Flow-$7,560-$8,721-$1,495-$5,076